Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer-Reference-Cited by-同舟云学术

Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer

Published:2022-11-09 Issue:22 Volume:65 Page:15102-15122
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Chen Weijiao¹,Ji Minghui¹,Cheng Hao¹²,Zheng Mingming¹,Xia Fei¹,Min Wenjian¹,Yang Huanaoyu¹,Wang Xiao¹,Wang Liping¹,Cao Lijuan²^ORCID,Yuan Kai¹,Yang Peng¹³^ORCID

Affiliation:

1. Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

2. State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism, China Pharmaceutical University, Nanjing 210009, China

3. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

Funder

Ministry of Education of the People's Republic of China

State Key Laboratory of Natural Medicines

Natural Science Foundation of Jiangsu Province

Government of Jiangsu Province

National Natural Science Foundation of China

Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link